APRIL
11.4.2024 11:59:30 CEST | Business Wire | Press release
Building on the success of its first transformation plan, APRIL is embarking on a new phase in its development with the ambition of becoming a European leader of global stature in the design, distribution and management of insurance solutions and financial products. The Group is planning an ambitious growth cycle, both organic and external, which will take it to a turnover of more than €1 billion by 2027.
With sales of €630m by 2023, 20% of which will be generated outside France, the Spring 2023 strategic plan has enabled APRIL to return to its basics and achieve sustainable growth. Today, the Group is looking ahead to a new stage in its development and has set itself the target of exceeding €1 billion in turnover by 2027.
« In an extremely competitive international environment, one of the most successful insurance brokers is French! Our nearly 3,000 employees are proud to continue APRIL's history and are in action to expand our global footprint, for the benefit of our tens of thousands of partners and our millions of customers, whom we support and protect on a daily basis, » states Eric Maumy, CEO of APRIL.
Four cardinal points to guide the Group's development:
the spirit of conquest, customer delight, technological performance and talent.
The spirit of conquest to become a global consolidator
With its sustained growth, APRIL Group will further accelerate its development based on three principles:
- Organic growth in its traditional markets: health and personal insurance for individuals, professionals and businesses, health insurance for expatriates and property and casualty insurance (auto, 2-wheeler, construction, real estate and yachting).
- Diversification into new growth drivers, as the Group has already begun to do with savings and asset management, which have become the Group's 4th business line.
- Internationalisation in all its markets, starting with international health, with strong ambitions in Europe, the Middle East and Asia.
In terms of diversification and internationalisation, APRIL Group intends to step up its external growth momentum, as demonstrated by the two deals completed since the beginning of 2024 with leading French savings company DLPK and UK two-wheeler specialist Lexham Insurance.
This consolidation drive will naturally go hand in hand with APRIL’s ongoing commitment to defending the interests of customers, particularly in terms of access to quality healthcare for as many people as possible.
Enchanting partners and customers to reinvent the insurance experience
Having improved its Net Promoter Score by more than 20 points in 4 years, the Group wants to accelerate its efforts to improve the experience of its partners and customers, by focusing on 3 key areas:
- Enhancing its service approach (easier access to healthcare networks and to teleconsultation facilities, etc.);
- Improving its digital systems - from the underwriting process to self-care areas and conversational tools;
- Strengthening and continually training the teams in contact with customers and partners, to offer them the very best in technology and human relations.
A technological transformation that incorporates Data & AI
APRIL Group plans to invests €70 million in its digital and technological transformation by 2027 with a twofold aim :
- Capitalising on data and artificial intelligence, via iterative projects that will be carried out within the group in France and internationally across all business lines to identify the potential for creating value for employees, customers and partners;
- Continuing to strengthen cyber security in an environment of heightened threat to all economic players.
Providing employees with a unique experience to attract and retain talent
With an average of 400 new hires per year since 2020, APRIL Group has strengthened its team, in particular by recruiting talent in high-tension professions, notably digital technology within its APRIL X hub and customer relations.
With its ambitions raised to 2027, the Group plans to offer a structured and enriched employee experience based on 3 levers:
- Developing talent through the knowledge factory, which will include strengthening the APRIL University and launching an Apprentice Training Centre;
- Focusing on our employees, with several agreements on intergenerational dynamics and inclusion & diversity, as well as the relocation of the Group's head office to more modern, collaborative offices in Lyon (France);
- Greater sharing of value, with the opening of the capital to all the Group's employees worldwide from April 2024.
True to its roots in the social economy, the Group plans to fuel its sustainable growth with a positive and real impact in terms of CSR, in particular through its APRIL Foundation, which focuses on the contribution of behavioural sciences to health prevention and promotion.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240411952024/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
